Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer (TRACC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04050345|
Recruitment Status : Recruiting
First Posted : August 8, 2019
Last Update Posted : August 8, 2019
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer|
|Actual Study Start Date :||December 5, 2016|
|Estimated Primary Completion Date :||December 5, 2024|
|Estimated Study Completion Date :||December 5, 2024|
Patients who have a diagnosis of large bowel cancer (in the colon) and the cancer is not metastatic.
Patients who have a diagnosis of large bowel cancer (in the Rectum) and the cancer is not metastatic.
- The Incidence of detectable circulating cell tumour derived DNA (ctDNA) in patients with stage II and III colorectal cancer (CRC) pre-operatively [ Time Frame: 3 years ]Measure if (ctDNA) is detectable in patients with stage II and III colorectal cancer (CRC) pre-operatively
- The correlation between detectable ctDNA at the first post-operative visit & disease free survival [ Time Frame: 5 years ]Measure the association between detectable ctDNA at the first post-operative visit & disease free survival
- Relationship between ctDNA detection before, during and after treatment [ Time Frame: 8 years ]To calculate the association between detectable ctDNA with disease free survival and overall survival at four time points during treatment.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04050345
|Contact: Annette Bryant||02086426011 ext firstname.lastname@example.org|
|Contact: Shelize Khakoo||Shelize.Khakoo@rmh.nhs.uk|
|The Royal Marsden NHS Foundation Trust||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Contact: Annette Bryant 02086426011 ext 4449 email@example.com|
|Contact: Sijy Pillai 02086426011 ext 3279 firstname.lastname@example.org|
|Sub-Investigator: Shelize Khakoo|
|Study Chair:||David Cunningham||Royal Marsden NHS Foundation Trust|